ClinicalTrials.gg
TerminatedNCT04261712Updated Jul 29, 2026

A Study to Evaluate the Long-Term Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Advance)

A Phase 2 interventional study of Paltusotine in Acromegaly, sponsored by Crinetics Pharmaceuticals Inc.. Terminated at 22 sites in 7 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-29.

Sponsored by Crinetics Pharmaceuticals Inc. (part of Vertex Pharmaceuticals Incorporated) · Phase 2, Interventional, and Treatment

Why this study was terminated
The study was stopped early for business reasons (not due to changes in the benefits or risks of paltusotine).
Phase
Phase 2
Study type
Interventional
Enrollment
43
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

A phase 2, open label, long-term extension study designed to evaluate the safety and efficacy of paltusotine (formerly CRN00808; an oral selective nonpeptide somatostatin receptor type 2 biased agonist) in subjects with acromegaly.

02

Conditions studied

  • Acromegaly

Browse trials for

Keywords

  • Acromegaly
  • ACROBAT
  • ADVANCE
  • Paltusotine
03

In context

Acromegaly

202 studies on the registry are indexed under Acromegaly; 19 are open to participants now.

This study's enrollment of 43 is close to the median of 43 across 115 interventional studies indexed under Acromegaly.

Browse Acromegaly studies →

Lead sponsor

Crinetics Pharmaceuticals Inc. is the lead sponsor of 19 studies on the registry; 3 are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 6 (50%) have results posted.

First submitted before Crinetics Pharmaceuticals Inc. became part of Vertex Pharmaceuticals Incorporated.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Completed one of the parent studies (Acrobat Evolve [CRN00808-02] or Acrobat Edge [CRN00808-03])
  2. Females must be non-pregnant and non-lactating, and either surgically sterile, , or using effective method(s) of
  3. Willing to provide signed

Exclusion criteria

Exclusion Criteria:

  1. concomitant disease including, but not limited to, cardiovascular disease; moderate or severe renal insufficiency; or significant liver disease (including cirrhosis)
  2. Pituitary radiation since completing participation in parent studies
  3. History or presence of except adequately treated basal cell and squamous cell carcinomas of the skin within the past 5 years
  4. Positive test at Screening for , surface antigen (HBsAg) or antibody (HCV-Ab).
  5. History of alcohol or substance abuse in the past 12 months
  6. Use of any drug (other than paltusotine) within the past 30 days or 5 half-lives, whichever is longer before Screening
  7. Any condition that in the opinion of the investigator would jeopardize the subject's appropriate participation in this study.
  8. Cardiovascular conditions or medications associated with prolonged or those which predispose subjects to heart rhythm abnormalities
  9. Subjects with symptomatic cholelithiasis
  10. Subjects with clinically significant abnormal findings during the Screening Period, and any other medical condition(s) or laboratory findings that, in the opinion of the Investigator, might jeopardize the subject's safety or ability to complete the study
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
43 participants (actual)

Study arms

  • Experimental
    Paltusotine

    Drug: Paltusotine

Interventions

  • Paltusotine, once daily by mouth

    Also known as: CRN00808

06

What researchers measure

Primary outcomes

  1. Incidence of treatment-emergent adverse events (TEAEs) throughout the study

    Time frame: Week 316

Secondary outcomes

  1. Change in insulin-like growth factor-1 (IGF-1) level

    Time frame: Week 16, Week 312

  2. Change in growth hormone (GH) level

    Time frame: Week 16, Week 312

07

Study locations

22 sites
  • Crinetics Study Site
    Los Angeles, California 90095, United States
  • Crinetics Study Site
    Chicago, Illinois 60611, United States
  • Crinetics Study Site
    Boston, Massachusetts 02114, United States
  • Crinetics Study Site
    Columbus, Ohio 43210, United States
  • Crinetics Study Site
    Pittsburgh, Pennsylvania 15212, United States
  • Crinetics Study Site
    Pittsburgh, Pennsylvania 15213, United States
  • Crinetics Study Site
    Dallas, Texas 75231, United States
  • Crinetics Study Site
    Curitiba, Paraná 80030-110, Brazil
  • Crinetics Study Site
    Rio de Janeiro, 20231, Brazil
  • Crinetics Study Site
    Rio de Janeiro, 21941, Brazil
  • Crinetics Study Site
    São Paulo, 01228, Brazil
  • Crinetics Study Site
    München, 80336, Germany
  • Crinetics Study Site
    Athens, 10676, Greece
  • Crinetics Study Site 1
    Athens, 11527, Greece
  • Crinetics Study Site 2
    Athens, 11527, Greece
  • Crinetics Study Site
    Thessaloniki, 54642, Greece
  • Crinetics Study Site
    Budapest, 1062, Hungary
  • Crinetics Study Site
    Budapest, 1083, Hungary
  • Crinetics Study Site
    Pécs, 7624, Hungary
  • Crinetics Study Site
    Belgrade, 11000, Serbia
  • Crinetics Study Site
    Coventry, United Kingdom
  • Crinetics Study Site
    Leeds, LS97TF, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04261712
Responsible party
Sponsor
First posted
Feb 10, 2020
Start date
Jan 29, 2020
Primary completion
Jun 30, 2026
Completion
Jun 30, 2026
Last update
Jul 29, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Paltusotine

Start the discussion